Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionCasdin Capital, LLC
Latest Disclosed Ownership75,000 shares
Latest Disclosed Value $ 24,815,250
Casdin Capital, LLC ownership in DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Casdin Capital, LLC filed a 13F-HR form disclosing ownership of 75,000 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $21,427,500 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 75,000 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $19,537,500 USD.

Casdin Capital, LLC has a history of taking positions in derivatives of the underlying security (DUL) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:DUL / Alnylam Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 75,000 0 0.00 24,815 -16.79 1.8791
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 75,000 20,000 36.36 29,824 18.91 1.8525
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 55,000 -26,500 -32.52 25,080 -5.63 2.0912
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 81,500 -38,500 -32.08 26,576 -17.98 2.4201
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 120,000 -20,000 -14.29 32,402 -1.64 2.6477
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 140,000 -30,000 -17.65 32,943 -29.54 2.1922
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 170,000 0 0.00 46,755 13.18 3.1171
2024-10-18 2024-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 170,000 -188,000 -52.51 41,310 -22.79 3.1543
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 170,000 -188,000 41,310 3.1665
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 358,000 163,000 83.59 53,503 43.35 3.9774
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 195,000 -5,000 -2.50 37,325 5.38 3.6638
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 200,000 -80,000 -28.57 35,420 -33.40 3.9202
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 280,000 10,000 3.70 53,183 -1.67 4.6477
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 270,000 -95,000 -26.03 54,086 -37.65 4.4552
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 365,000 -283,000 -43.67 86,742 -33.12 6.7208
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 648,000 -157,000 -19.50 129,704 10.47 8.5201
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 805,000 -195,000 -19.50 117,409 -28.10 9.9271
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,000,000 0 0.00 163,290 -3.71 7.3217
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,000,000 0 0.00 169,580 -10.18 4.7796
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,000,000 0 0.00 188,810 11.38 4.6997
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,000,000 120,000 13.64 169,520 36.44 4.3032
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 880,000 100,000 12.82 124,247 22.56 3.7004
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 780,000 160,000 25.81 101,377 12.30 3.0034
2020-11-16 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 620,000 70,000 12.73 90,272 10.82 4.0420
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 550,000 -35,000 -5.98 81,461 27.93 4.8209
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 585,000 70,000 13.59 63,677 7.36 6.7597
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 515,000 -85,000 -14.17 59,313 22.92 5.4545
2020-01-03 2019-09-30 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 600,000 -50,000 -7.69 48,252 2.31 4.9935
2019-11-12 2019-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 600,000 0 48,252 4.8270
2019-11-12 2019-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 600,000 -50,000 48,252 6,476.1906
2019-08-13 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 650,000 205,000 46.07 47,164 13.42 4.4145
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 445,000 90,000 25.35 41,585 60.67 4.5679
2019-02-13 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 355,000 85,000 31.48 25,883 9.53 4.4282
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 270,000 0 0.00 23,630 -11.14 2.8720
2018-08-20 2018-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 270,000 20,000 8.00 26,592 -10.69 3.7190
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 270,000 20,000 26,592
2018-05-15 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 250,000 50,000 25.00 29,775 17.18 5.2364
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 200,000 0 0.00 25,410 8.14 6.1880
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 200,000 95,000 90.48 23,498 180.57 6.6350
2017-08-14 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 105,000 50,000 90.91 8,375 197.09 3.0978
2017-05-15 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 55,000 -30,000 -35.29 2,819 -11.41 1.6630
2017-02-14 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 85,000 46,000 117.95 3,182 20.39 2.6281
2016-11-14 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 39,000 -33,500 -46.21 2,643 -34.30 2.1401
2016-08-15 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 72,500 -17,500 -19.44 4,023 -28.78 4.0044
2016-05-09 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 90,000 30,000 50.00 5,649 0.02 6.4838
2016-02-08 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 60,000 60,000 5,648 4.9903
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 20,000 3,542 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.